Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA). It is mainly used to treat increased bleeding risk due to thrombocytopenia in adult patients with chronic liver disease, especially for platelet elevation before invasive procedures such as surgery. It acts as a targeted therapy by stimulating the maturation of megakaryocytes in the bone marrow and platelet production.
Mechanism of Action and Indications
Mechanism of Action
Lusutrombopag selectively activates the thrombopoietin (TPO) receptor, triggering the intracellular JAK-STAT signaling pathway to promote megakaryocyte proliferation, differentiation, and maturation, ultimately increasing platelet production. Compared with similar drugs, its oral administration offers greater convenience.
Core Indication
Thrombocytopenia Associated with Chronic Liver Disease
Patients with chronic liver disease often develop thrombocytopenia due to abnormal liver function. Lusutrombopag can significantly increase platelet counts and reduce bleeding risk during invasive procedures including liver biopsy and surgery.
Other Potential Indications
Some studies are investigating its use in chemotherapy-induced thrombocytopenia or immune thrombocytopenia (ITP), but use must strictly follow clinical guidelines.
Clinical Application and Research Progress
Lusutrombopag is currently approved in multiple countries for selected patients with thrombocytopenia. Studies show it can significantly increase platelet levels within 5–7 days, with an efficacy rate exceeding 70%. Phase III clinical trials for chemotherapy-induced thrombocytopenia are ongoing, and preliminary results suggest manageable safety.
Future research directions include:
Optimizing dosing regimens to reduce side effects;
Exploring potential in diseases such as aplastic anemia;
Evaluating long-term safety.
